Precision Therapeutics Increases Equity Stake in Helomics to 25%


[End Subhead]
[Start Distributor]
GlobeNewswire 14-Mar-2018 4:30 PM
[End Distributor]
MINNEAPOLIS, March 14, 2018 (GLOBE NEWSWIRE) -- Precision Therapeutics Inc. (NASDAQ:AIPT) (Precision or the Company), formerly Skyline Medical, a company focused on applying artificial intelligence to personalized medicine and drug discovery, announced today that it has converted a previous $500,000 loan to Helomics into a 5% equity stake. This follows the purchase of preferred stock convertible into 20% of the outstanding common stock ofHelomics Corporation in January 2018,bringing the Companys total ownership of Helomics to 25%.
Headquartered inPittsburgh, Pennsylvania, Helomics has established operations that bridge two emerging areas of the healthcare industry: precision medicine and big data. Helomics competitive advantage lies in its proprietary D-CHIP database, which contains de-identified data compiled from more than a decade of clinical testing of tumor responses to drugs, coupled to an Artificial Intelligence (AI)-powered bioinformatics engine which generates actionable scientific insights from this rich data. These insights are used by BioPharma companies in the research and development of targeted cancer treatments for any given patient profile, driving improved patient outcomes.
Dr. Carl Schwartz, Chief Executive Officer of Precision Therapeutics, commented, We are pleased to increase our equity stake in Helomics as we rapidly advance our strategy to position Precision Therapeutics as a leading provider of CRO and diagnostic services to the precision medicine market. Our aim is to facilitate the development of personalized cancer treatments by bringing together some of the most advanced bioinformatics and artificial intelligence technologies on the market, and applying them to the fast-growing precision medicine space. We will leverage Helomicss proprietary DChip AI platform, which contains the drug response profiles of over 149,000 patient tumors, in collaboration with our next generation patient derived (PDx) TumorGenesis tumor models, to provide actionable insights for clients in the pharmaceutical, diagnostic, and biotech sectors. We intend to build out the DChips high-quality data set in order to drive new client agreements, improve patient outcomes and grow revenues.
AboutPrecision Therapeutics Inc.
Precision Therapeutics(NASDAQ:AIPT) operates in two business areas: first, applying artificial intelligence to personalized medicine and drug discovery to provide personalized medicine solutions for clients in the pharmaceutical, diagnostic, and biotech industries, and second, production of theFDA-approved STREAMWAY System for automated, direct-to-drain medical fluid disposal.
Precision Therapeutics'CRO services business is committed to improving the effectiveness of cancer therapy using the power of artificial intelligence (AI) applied to rich data diseases databases. This business has launched withPrecision Therapeutics'investment inHelomics Corporation, a precision diagnostic company and integrated clinical contract research organization whose mission is to improve patient care by partnering with pharmaceutical, diagnostic, and academic organizations to bring innovative clinical products and technologies to the marketplace. In addition to its proprietary precision diagnostics for oncology, Helomics offers boutique CRO services that leverage our patient-derived tumor models, coupled to a wide range of multi-omics assays (genomics, proteomics and biochemical), and a proprietary bioinformatics platform (D-CHIP) to provide a tailored solution to our client's specific needs. Helomics is 25% owned by Precision Therapeutics. Helomics is headquartered inPittsburgh, Pennsylvaniawhere the company maintains state-of-the-art, CLIA-certified, clinical and research laboratories. For more information, please visitwww.Helomics.com.
Precision Therapeutics has also announced the formation of a subsidiary, TumorGenesis to pursue a new rapid approach to growing tumors in the laboratory, which essentially fools the cancer cells into thinking they are still growing inside the patient.
Precision Therapeuticsand Helomics have also announced a proposed joint venture withGLG Pharmafocused on using their combined technologies to bring personalized medicines and testing to ovarian and breast cancer patients, especially those who present with ascites fluid (over one-third of patients). The growth strategy in this business includes securing new partnerships and considering acquisitions in the precision medicine space.
Sold through the Skyline Medical business ofPrecision Therapeutics, The STREAMWAY System virtually eliminates staff exposure to blood, irrigation fluid and other potentially infectious fluids found in the healthcare environment. Antiquated manual fluid handling methods that require hand carrying and emptying filled fluid canisters present an exposure risk and potential liability. Skyline Medical's STREAMWAY System fully automates the collection, measurement, and disposal of waste fluids and is designed to: 1) reduce overhead costs to hospitals and surgical centers; 2) improve compliance withOSHAand other regulatory agency safety guidelines; 3) improve efficiency in the operating room, and radiology and endoscopy departments, thereby leading to greater profitability; and 4) provide greater environmental stewardship by helping to eliminate the approximately 50 million potentially disease-infected canisters that go into landfills each year in the U.S. For additional information, please visitwww.skylinemedical.com.
Forward-looking Statements
Certain of the matters discussed in this announcement contain forward-looking statements that involve material risks to and uncertainties in the Company's business that may cause actual results to differ materially from those anticipated by the statements made herein. Such risks and uncertainties include risks related to the proposed joint ventures, including the need to negotiate the definitive agreements for the joint ventures; possible failure to realize anticipated benefits of the joint ventures; and costs of providing funding to the joint ventures. Other risks and uncertainties relating to the Company include, among other things, current negative operating cash flows and a need for additional funding to finance our operating plan; the terms of any further financing, which may be highly dilutive and may include onerous terms; unexpected costs and operating deficits, and lower than expected sales and revenues; sales cycles that can be longer than expected, resulting in delays in projected sales or failure to make such sales; uncertain willingness and ability of customers to adopt new technologies and other factors that may affect further market acceptance, if our product is not accepted by our potential customers, it is unlikely that we will ever become profitable; adverse economic conditions; adverse results of any legal proceedings; the volatility of our operating results and financial condition; inability to attract or retain qualified senior management personnel, including sales and marketing personnel; our ability to establish and maintain the proprietary nature of our technology through the patent process, as well as our ability to possibly license from others patents and patent applications necessary to develop products; the Company's ability to implement its long range business plan for various applications of its technology; the Company's ability to enter into agreements with any necessary marketing and/or distribution partners and with any strategic or joint venture partners; the impact of competition, the obtaining and maintenance of any necessary regulatory clearances applicable to applications of the Company's technology; and management of growth and other risks and uncertainties that may be detailed from time to time in the Company's reports filed with theSecurities and Exchange Commission, which are available for review atwww.sec.gov. This is not a solicitation to buy or sell securities and does not purport to be an analysis of the Company's financial position. See the Company's most recent Annual Report on Form 10-K, and subsequent reports and other filings atwww.sec.gov.
Contacts: Investor RelationsKCSA Strategic CommunicationsElizabeth Barker(212) 896-1203ebarker@kcsa.com
MONEYINFO, LLC Charles Moskowitz 617-827-1296info@moneyinfo-llc.com

Wait, Before You Leave...